Clinical Trial Update: Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated a novel capecitabine dosing schedule in combination with lapatinib for HER2-positive, trastuzumab-refractory metastatic breast cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-08-15